A phase II study of erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy

Trial Profile

A phase II study of erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Bladder cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 19 May 2017 Status changed from active, no longer recruiting to completed.
    • 22 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
    • 10 Dec 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top